Mineralys Therapeutics, Inc. (MLYS) stock
MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$14.48−0.05 (-0.34%)
Close on Nov 17, 2026Market cap $1.28BP/E –Yield –
Mineralys Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Mineralys Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $301.59M, up 72.6% year over year. For fiscal 2025 it was $132.01M, down 21.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.01M | -21.7% |
| FY2024 | Dec 31, 2024 | $168.58M | +139.6% |
| FY2023 | Dec 31, 2023 | $70.36M | +168.0% |
| FY2022 | Dec 31, 2022 | $26.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $221.38M | +478.3% |
| Q1 FY2026 | Mar 31, 2026 | $24.37M | -35.7% |
| Q4 FY2025 | Dec 31, 2025 | $24.40M | -45.2% |
| Q3 FY2025 | Sep 30, 2025 | $31.45M | -41.7% |
| Q2 FY2025 | Jun 30, 2025 | $38.28M | -2.5% |
| Q1 FY2025 | Mar 31, 2025 | $37.88M | +23.2% |
| Q4 FY2024 | Dec 31, 2024 | $44.57M | +88.2% |
| Q3 FY2024 | Sep 30, 2024 | $53.99M | +139.9% |
| Q2 FY2024 | Jun 30, 2024 | $39.27M | +230.5% |
| Q1 FY2024 | Mar 31, 2024 | $30.75M | +150.2% |
| Q4 FY2023 | Dec 31, 2023 | $23.69M | +203.0% |
| Q3 FY2023 | Sep 30, 2023 | $22.50M | +271.3% |
| Q2 FY2023 | Jun 30, 2023 | $11.88M | +112.4% |
| Q1 FY2023 | Mar 31, 2023 | $12.29M | +81.4% |
| Q4 FY2022 | Dec 31, 2022 | $7.82M | – |
| Q3 FY2022 | Sep 30, 2022 | $6.06M | – |
| Q2 FY2022 | Jun 30, 2022 | $5.60M | – |
| Q1 FY2022 | Mar 31, 2022 | $6.78M | – |
See a number that looks wrong?